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During a 15-year period, the incidence of type 1 diabetes has doubled in 
Lithuania, while increasing by a third in England; however, England still 
has a higher incidence. Analysis of sera collected from non-diabetic school-
children from Lithuania and England more than 20  years ago showed a 
similar number of multiple autoantibody-positive schoolchildren between 
the populations, but a higher prevalence of islet antigen-2 autoantibodies 
(IA-2A) in English schoolchildren. We aimed to use recently developed, 
more specific islet autoantibody tests to characterize differences in humoral 
autoimmunity between these two general population cohorts in greater 
detail. Samples from 88  Lithuanian and 133  English schoolchildren previ-
ously found islet autoantibody-positive were selected for measurement of 
additional islet autoantibodies by radioimmunoassay. Samples were tested 
for autoantibodies to zinc transporter 8 (ZnT8A), GAD (96–585), the pro-
tein tyrosine phosphatase region of islet antigen-2 (PTPA) and the related 
IA-2βA, while autoantibodies to IA-2A were reassayed using the current 
harmonized method. IA-2-related autoantibodies PTPA (0·13 versus 0·45%, 
P  =  0·027) and IA-2βA (0 versus 0·35%, P  <  0·001), but not IA-2A meas-
ured using the harmonized method, were less common in Lithuanian 
compared to English schoolchildren. Lithuanian schoolchildren who were 
islet autoantibody-positive were positive for fewer biochemical autoanti-
bodies compared with English schoolchildren (P  =  0·043). Background 
rates of islet autoimmunity in childhood differ subtly between countries, 
which have different incidences of type 1 diabetes. The optimal screening 
strategy (age and combination of markers) for detection of islet autoim-
munity may vary between countries, dependent upon the pattern of au-
toantibodies found in the general population.
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Introduction
Environmental factors are often cited as an explanation 
for differences in incidence of type 1 diabetes; within 
Europe the incidence ranged approximately 10-fold from 
5·8 of 100  000 (Macedonia) to 56 of 100  000 (Finland) 
between 2000 and 2005 [1]. We found previously that 
the prevalence of autoantibodies to islet antigen-2 
(IA-2A) was 10-fold lower (0·2 versus 2·4%) in 3053 
schoolchildren from Lithuania, with a diabetes incidence 
of 7·1 cases per 100  000/year, compared with 2860 
schoolchildren of a similar age from the United Kingdom, 
which at that time had an incidence of 17 cases per 
100  000/year [2]. The frequency of autoantibodies to 
insulin (IAA), glutamate decarboxylase (GADA) and 
multiple autoantibodies [mAab, which included islet cell 
antibodies (ICA)] was similar in the two groups. Although 
measurement of biochemical autoantibodies (where the 
antigen is known) is now common, ICA are still included 
as a secondary measure within TrialNet, where their 
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inclusion aided disease prediction [3]. A later study 
comparing islet autoantibody prevalence in schoolchil-
dren with similar ethnic origins (Finland and Russian 
Karelia), but different incidences of type 1 diabetes, also 
found an increased IA-2A prevalence in schoolchildren 
from the population with a higher incidence [4]. Since 
our original paper, autoantibodies to zinc transporter 8 
(ZnT8A) have been discovered and shown to be useful 
for disease prediction. Both ZnT8A and IA-2βA, a homo-
logue of IA-2A, are associated with rapid progression 
to disease [5]. An international harmonized protocol 
for measurement of IA-2A has also been established 
[6], while measurement of autoantibodies using a trun-
cated radiolabel [GAD(96–585)] improves specificity 
compared with using full-length antigen [7].
We previously investigated autoantibody prevalence 
at diagnosis in patients from the same geographical 
region as the English schoolchildren during a 17-year 
time-span, when type 1 diabetes incidence rose and 
prevalence of ZnT8A and IA-2A increased [8]. The 
prevalence of IA-2βA and autoantibodies recognizing 
the protein tyrosine phosphatase region of IA-2 (PTPA) 
also increased during this time-span. Given our previous 
data and the association between diabetes incidence and 
prevalence of ZnT8A and IA-2A, we hypothesized that 
autoantibodies associated with a higher risk of diabetes 
[ZnT8A, GADA (96–585) and IA-2A/IA-2βA epitopes] 
would also differ in the Lithuanian and English school-
child populations.
Methods
The Lithuanian and English schoolchild samples have been 
previously described [2]. Serum samples from 3053 
Lithuanian schoolchildren were available for study; the 
median age was 11·7  years (age range  =  5·5–15·0  years), 
with 1449 (47%) boys. Samples from 2860 English school-
children were also available; the median age was 11·4 
years (age range  =  9·0–13·8 years), with 1488 (52%) boys. 
Samples have been stored at −20°C since sample collec-
tion between 1994 and 1998. The two sample collections 
have been approved by local ethics committees and the 
study was performed according to the principles of the 
Declaration of Helsinki.
Autoantibodies for GAD (96–585), IA-2, IA-2β and 
PTP were measured as previously described [6–8]. Islet 
autoantibody units were derived from standard curves 
of serially diluted positive sera. The threshold for posi-
tivity was set at 1·8 units; the 97·5th percentile of 523 
of the non-diabetic English schoolchildren for autoan-
tibodies was measured using ZnT8 (325R) or ZnT8 
(325W). The positivity threshold for GAD (96A) was 
set at 12·8 units, the 97·5th percentile of 222 English 
schoolchildren. The threshold for IA-2A measured using 
the harmonized method was set at 1·4 DK  units/ml, 
the 99·2nd percentile of 500 non-diabetic adult controls 
[6]. For PTPA and IA-2βA the thresholds were set at 
3 standard deviations (s.d.) of 270 of the English school-
children; 0·57 and 0·93 units, respectively. Samples were 
measured in duplicate; where the error was ≥  30% the 
results were inspected and samples with results close 
to the threshold for positivity were repeated. Samples 
were also repeated where negative, low, medium or high 
positive controls were out of range.
Statistical analysis
The percentage of people positive for a given autoantibody 
was compared between Lithuanian and English school-
children using Fisher’s exact test. The number of islet 
autoantibodies was compared using the χ2 test. Mann–
Whitney U-testing was used to compare autoantibody titres 
within individuals positive for each autoantibody. Statistical 
analysis was carried out using Prism version 6 software 
(GraphPad Software, Inc., La Jolla CA, USA). A 
P-value  <  0·05 was considered significant.
Results
ZnT8A and GADA
Data for GADA, IA-2A, IAA and ICA tested historically 
were already available; originally, ICA and IAA were only 
tested in GADA- and/or IA-2A-positive individuals 
(n = 221), with 27 (12·2%)- and 19 (8·6%)-positive, respec-
tively. Samples previously positive for GADA and/or IA-2A 
from schoolchildren (88 Lithuanian and 133 English school-
children, Fig. 1) were selected for measurement of ZnT8A 
using published methods [8]. Of these, samples from one 
Lithuanian and one English child (who were not mAab-
positive) were not of sufficient volume for ZnT8A meas-
urement. Schoolchildren negative for GADA and IA-2A 
(2965 Lithuanian and 2727 English schoolchildren) were 
considered ZnT8A negative, because in an unpublished 
screen of 1400 English 7-year-olds negative for IA-2A and 
GADA only four were ZnT8A-positive, and other studies 
including The Environmental Determinants of Diabetes in 
the Young (TEDDY) also use this protocol [9].
Overall, four (0·13%) Lithuanian and six (0·14%) English 
schoolchildren tested positive for ZnT8A [P  =  not sig-
nificant (n.s.), Supporting information, Fig. S1a]. In previous 
GADA-positive schoolchildren, GADA were remeasured 
using GAD (96–585), 47 of 80 (58%) Lithuanian and 36 
of 70 (51%) English schoolchildren were positive for 
autoantibodies recognizing GAD (96–585) (P  =  n.s., 
Supporting information, Fig. S1b). Truncated GADA screen-
ing identified almost all mAab positives, but only half of 
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the school children were previously GADA-positive, sug-
gesting that it identifies schoolchildren at higher risk of 
progression to diagnosis of diabetes.
IA-2 related autoantibodies
In seven Lithuanian and 70 English previously IA-2A-
positive schoolchildren, IA-2A, IA-2PTPA and IA-2βA were 
measured using the harmonized method [6,8]. When IA-2A 
were remeasured, five (0·16%) Lithuanian and 10 (0·35%) 
English schoolchildren were positive (P  =  n.s., Supporting 
information, Fig. S1c). In contrast, however, PTPA and 
IA-2βA were less common in Lithuanian schoolchildren 
(0·10 and 0% of 3053, respectively) compared with English 
schoolchildren (0·42 and 0·35% of 2860, with P  =  0·018 
and P  <  0·001, respectively, Supporting information, Fig. 
S1d). These results were mirrored, although not statistically 
different for IA-2A titres (Fig. 2). Several English school-
children had titres of IA-2A, PTPA and IA-2βA more 
than 20-fold higher than any of the Lithuanian 
schoolchildren.
Number of autoantibodies
Overall, 24 schoolchildren (10 Lithuanian and 14 English) 
were mAab-positive by combinations of GADA/IA-2A/
IAA/ZnT8A testing (Supporting information, Fig. S1a). 
This number increased to 41 (24  Lithuanian and 17 
English) if ICA were considered an independent autoan-
tibody (Supporting information, Fig. S2). Interestingly, 
Fig. 1. Testing strategy. Historic islet autoantibody testing [2] is summarized in the grey boxes, including retesting of islet antigen-2 autoantibodies 
(IA-2A) and measurement of autoantibodies to insulin (IAA) in samples positive for IA-2A and/or autoantibodies to glutamic acid decarboxylase 
(GADA). Previous results were used to select samples for current islet autoantibody testing. The autoantibody testing strategy in the current study is 
indicated in the white boxes. Autoantibodies to zinc transporter 8 (ZnT8A) were tested in samples previously positive for IA-2A and/or GADA. GADA 
(96–585) were tested in samples previously GADA-positive. IA-2A-related autoantibodies were tested in samples previously positive for IA-2A. 















































































Fig. 2. Titres of islet antigen-2 autoantibodies (IA-2A) in Lithuanian 
(Lit, n = 7 or 3053) and English (Eng, n = 70 or 2860) schoolchildren. 
With IA-2A measured using the harmonized method (threshold 1·4 
DK units/ml), protein tyrosine phosphatase region of IA-2 (PTPA) 
(threshold 0·57 units), IA-2βA (threshold 0·93 units) and local IA-2A 
(threshold 0·94 units). Black diamonds = positive individuals, grey 
diamonds = negative individuals. Differences in titre were not 
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ICA was more prevalent in the Lithuanian schoolchildren 
with autoantibodies recognizing GAD (96–585) and full-
length GAD [12 of 50 (24%)], compared with those 
with autoantibodies recognizing full-length GAD alone 
[two of 32 (6·3%, P = 0.037)]. The number of Lithuanian 
schoolchildren considered mAab-positive doubled when 
ICA was considered. When newer, more specific methods 
were used, only 18  schoolchildren remained mAab-
positive for biochemical autoantibodies (Supporting 
information, Fig. S1c). There was no difference between 
the prevalence of mAab in Lithuanian (n  =  9) and 
English schoolchildren (n  =  9). However, within autoan-
tibody positives, Lithuanian schoolchildren had three or 
four autoantibodies less frequently compared with English 
schoolchildren (3·4 versus 17%, P = 0·043, Fig. 3). Logistic 
regression analysis, including age and sex, confirmed 
the results obtained by all univariate analyses (data not 
shown).
Discussion
After new islet autoantibody measurement and analysis, 
Lithuanian schoolchildren have a lower frequency of PTPA 
and IA-2βA compared with English schoolchildren. The 
number of Lithuanian schoolchildren with three or four 
islet autoantibodies was also lower. The frequency of ZnT8A 
and autoantibodies recognizing GAD (96–585) was similar 
in the two groups.
A large number (n  =  5913) of schoolchildren were 
screened; autoantibody-positive schoolchildren were rare, 
but some differences in the prevalence of antibodies were 
observed. In contrast to our previous paper, autoantibodies 
were measured concurrently for all schoolchildren. Assay 
variation cannot, therefore, explain the observed 
differences.
The intracellular region of IA-2 contains the PTP region. 
It is therefore expected that almost all individuals with 
antibodies that bind PTP would also bind the IA-2ic probe 
used for the harmonized assay. This was not the case for 
our study, which could be due to false positive results; 
for this reason, these samples were retested. Four of six 
were confirmed PTPA-positive, and these results were 
included in the above analysis. We note, however, that if 
IA-2A-negative schoolchildren are considered PTPA-
negative there is no difference between Lithuanian and 
English schoolchildren for PTPA (n  =  3 versus n  =  8, 
respectively, P  =  0·135). The thresholds used to assign 
antibody positivity for IA-2-related antibodies have been 
previously published applied to newly diagnosed children 
[8]; nevertheless, they were set using different populations 
of healthy individuals. When tested on the same popula-
tion the harmonized threshold appears slightly more strin-
gent than for PTPA and IA-2βA. However, even if the 
threshold was lowered from 1·4 to 0·9 DK units, only 
three additional (one Lithuanian and two English) school-
children would be positive (data not shown). Although 
large numbers of samples have been tested from both 
populations, this still represents a small number of children 
with measurable antibody responses, limiting the power 
of the current study. The data from the previous paper 
(n  =  7 statistical inferences) and current paper (n  =  13 
statistical inferences), IA-2A/PTPA/IA-βA tests and indi-
vidual versus antibody numbers are not truly independent, 
therefore we have not applied correction for multiple test-
ing. However, if Bonferroni correction was applied, the 
difference between IA-2βA prevalence in English and 
Lithuanian schoolchildren would be replicated 
(pcorr  =  0·014).
Samples for genetic analysis were not available. Genetics 
is also unlikely to explain the decreased prevalence of 
autoantibodies related to IA-2A, as human leucocyte antigen 
(HLA) class II haplotypes associated with type 1  diabetes 
were similar in Lithuanian schoolchildren compared with 
other European Caucasian populations [10]. However, it 
should be noted that higher-risk HLA haplotypes were 
more frequent in people with diabetes in Sweden compared 
to Lithuania [11]. Although ZnT8A were not measured 
in all individuals, previous unpublished data suggest that 
among non-diabetic children single ZnT8A-positive indi-
viduals were rare. In the current study, we were unable 
to assess the prevalence of schoolchildren single autoan-
tibody-positive for ZnT8A or autoantibodies to GAD 
(96–585) due to this testing strategy.
Fig. 3. Number of autoantibodies as a percentage of the 53 Lithuanian 
and 47 English schoolchildren found autoantibody-positive using 
updated assays. Based on autoantibodies to insulin (IAA), glutamic 
acid decarboxylase (GADA) (96–585), harmonized islet antigen-2 
autoantibodies (IA-2A) (and/or IA-2βA) and zinc transporter 8 
(ZnT8A) (ESM Fig. S1c). Black = 4, dark grey = 3, light grey = 2, 
white = 1 autoantibody. A smaller proportion of Lithuanian 
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We were also unable to confirm current progression 
to clinical disease for these schoolchildren. However, 
studies of the offspring of people with diabetes show 
that young children with multiple autoantibodies develop 
diabetes during childhood [12], suggesting that most of 
these children will progress to diabetes. Recent data 
suggest that risk of diabetes is equally high in young 
children with multiple autoantibodies from the general 
population [13]. Our study found a similar prevalence 
of multiple islet autoantibodies to this study from Bavaria 
(0·3%), despite a difference in the age of the children 
tested.
We previously speculated that the incidence of type 
1 diabetes would rise rapidly in Lithuania due to similar 
frequencies of multiple islet autoimmunity in the school-
child populations [2], and indeed incidence in Lithuania 
doubled between 1989–93 and 2004–08, whereas in 
England it rose by only a third [1]. However, the inci-
dence of diabetes in England is still twice as high as 
in Lithuania [1] , suggesting that the subtle differences 
in the autoantibody profiles between the populations 
may be important, particularly in determining progres-
sion rate. The incidence of autoimmune diabetes in adults, 
however, is not well characterized in either population; 
Lithuanian schoolchildren with islet autoimmunity may 
be diagnosed as adults.
This study found no difference in IA-2A prevalence 
between Lithuanian and English schoolchildren in con-
trast to our previous findings, and this may be accounted 
for by subsequent optimization of assays. The harmonized 
assay currently employed for IA-2A appears to be more 
specific than the previous assay format. However, in the 
2009 Diabetes Antibody Standardization workshop our 
harmonized and local assays for IA-2A performed simi-
larly (specificity 97 versus 97, sensitivity 62 versus 64). 
In addition, at the time of the original report IA-2A-
positive individuals were retested for IA-2A using the 
same method; after reanalysis there was still a difference 
between the cohorts, with seven of seven Lithuanian 
and 30 of 70  English schoolchildren defined as 
positive.
Both PTPA and IA-2βA arise later in the humoral response 
[14] before type 1 diabetes and are associated with rapid 
progression [5]. Autoantibody-positive Lithuanian school-
children were positive for fewer autoantibodies than autoan-
tibody-positive English schoolchildren. This suggests that 
English schoolchildren at risk of diabetes have experienced 
more epitope- and antigen-spreading than Lithuanian school-
children of a similar age, which could be due to differing 
environmental determinants. In addition, Swedish children 
at diagnosis with diabetes were positive for more autoan-
tibodies than Lithuanian children, which supports differing 
pathogenesis in the two countries [11]. The overlap of ICA 
and autoantibodies recognizing GAD (96A) suggests that 
ICA may be more effective at recognizing this higher dia-
betes risk epitope, and could explain the added benefit of 
ICA testing within TrialNet [3].
Broadly, these new results support our previous obser-
vation that certain aspects of the autoantibody profile 
associated with more rapid progression are different in 
Lithuanian compared with English schoolchildren. The 
optimum age and combination of islet autoantibodies 
to use for screening different populations for diabetes 
risk may vary, therefore; for example, GADA alone may 
be a good primary screen for Lithuanian 
schoolchildren.
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Fig. S1. Historic islet autoantibody testing (Marčiulionytė et 
al. 2001 []) is indicated for GADA, IA-2A, and IAA (circles 
with solid borders). Current islet autoantibodies testing for 
ZnT8A, GADA (96-585), IA-2A DK, PTPA, and IA-2βA (bro-
ken borders). a indicates a samples that could not be tested 
for at least one of the autoantibodies. Loss of multiple auto-
antibody positive status is indicated by red text. b indicates 
one individual from this category was considered multiple 
autoantibody positive (mAab +ve) with previous testing but 
is not with new method. mAab +ve individuals are indi-
cated in bold blue text. a) addition of ZnT8A in previously 
Aab+ve individuals, b) addition of GAD (96-585) testing in 
previously GADA positive, c) addition of harmonized IA-2A 
testing in previously IA-2A positive, d) breaking down the 
IA-2A epitope responses.
Fig. S2. Addition of ICA to biochemical autoantibody test-
ing is indicated, i.e. 2/3 indicates that 2 out of 3 individu-
als in this area of the diagram were ICA positive. Historic 
islet autoantibody testing (Marčiulionytė et al. 2001 []) is 
indicated for GADA, IA-2A, and IAA (circles with solid 
borders). Current islet autoantibodies testing for ZnT8A, 
GADA (96-585), IA-2A DK, PTPA, and IA-2βA (broken 
borders). a indicates a samples that could not be tested for 
at least one of the autoantibodies. Loss of multiple autoan-
tibody positive status is indicated by red text. b indicates 
one individual from this category was considered multiple 
autoantibody positive (mAab +ve) with previous testing 
but is not with new methods. Individuals with more than 
1 positive test are indicated in bold blue text. a) Historic 
GADA, IA-2A, and IAA testing with addition of ZnT8A b) 
Historic IAA testing with addition of ZnT8A, and new test-
ing for GADA (96-585) and IA-2A (IA-2A DK, PTPA, and/
or IA-2βA).
